| Literature DB >> 35153518 |
Pungkava Sricharoen1, Chaithawat Chueluecha1, Chaiyaporn Yuksen1, Chetsadakon Jenpanitpong1.
Abstract
BACKGROUND: Sepsis causes high mortality in vulnerable groups such as hematologic malignancy (HM) patients. There are various early warning scores of sepsis, eg, qSOFA, SOFA, and Ramathibodi Early Warning Score (REWS). This study aimed to compare REWS, qSOFA, and SOFA in predicting severe complications in hematologic malignancy patients visiting ED.Entities:
Keywords: SOFA; early warning score; hematologic malignancy; qSOFA; sepsis
Year: 2022 PMID: 35153518 PMCID: PMC8827160 DOI: 10.2147/OAEM.S345308
Source DB: PubMed Journal: Open Access Emerg Med ISSN: 1179-1500
Figure 1The protocols of data collection.
Parameter of REWS (Ramathibodi Early Warning Score)
| Score | RR | SpO2 | Temp | SBP | HR | AVPU |
|---|---|---|---|---|---|---|
| 3 | ≤10 | ≤84 | ≤33.9 | ≤89 | ≤39 | U |
| 2 | 85–89 | 34–34.9 | P | |||
| 1 | 90–92 | 35–35.9 | 90–99 | 40–49 | V | |
| 0 | 11–20 | ≥93 | 36–37.9 | 100–199 | 50–99 | A |
| 1 | 21–30 | 38–38.9 | 100–109 | |||
| 2 | 31–35 | ≥39 | ≥200 | 110–129 | ||
| 3 | ≥130 |
Abbreviations: SpO2, estimate of arterial oxygen saturation; SBP, systolic blood pressure; A, Alert; V, Verbal; P, pain; U, Unresponsive.
The Patient’s Characteristic and Outcome of the Cohort
| Variables | Total, N = 124 | Serious Complication | P-value | Death, N = 20 | Survive N = 104 | P-value | |
|---|---|---|---|---|---|---|---|
| Yes, N = 51 | No, N = 73 | ||||||
| Age, years | 56 ± 16.8 | 59.8 ± 15.7 | 54.07 ± 17.3 | 0.060 | 61.8 ± 17.2 | 55.4 ± 16.7 | 0.123 |
| Gender, male % | 58 (46.8) | 23 (45.1) | 35 (47.9) | 0.855 | 13 (65) | 45 (43.3) | 0.093 |
| Comorbidities, N (%) | |||||||
| DM | 26 (21) | 8 (15.7) | 18 (24.7) | 0.865 | 3 (15) | 23 (22.2) | 0.562 |
| HT | 43 (34.7) | 20 (39.2) | 23 (31.5) | 0.444 | 8 (40) | 35 (33.6) | 0.613 |
| CKD | 10 (8.06) | 4 (7.84) | 6 (8.22) | 1.00 | 1 (5) | 9 (8.65) | 1.00 |
| Type of hematologic malignancies, N (%) | |||||||
| AML | 36 (29) | 14 (27.45) | 22 (30.14) | 0.253 | 7 (35) | 29 (27.88) | 0.746 |
| ALL | 8 (6.45) | 5 (9.8) | 3 (4.11) | 1 (5) | 7 (6.73) | ||
| CML | 10 (8.06) | 2 (3.92) | 8 (10.96) | 1 (5) | 9 (8.65) | ||
| CLL | 2 (1.61) | 1 (1.96) | 1 (1.37) | 1 (5) | 1 (0.96) | ||
| DLBCL | 12 (9.68) | 5 (9.8) | 7 (9.59) | 1 (5) | 11 (10.58) | ||
| Relapse/refractor DLBCL | 3 (2.41) | 1 (9.8) | 2 (2.74) | 0 | 3 (2.88) | ||
| T-cell lymphoma | 8 (6.45) | 6 (11.76) | 2 (2.74) | 2 (10) | 6 (5.77) | ||
| Multiple myeloma | 12 (9.68) | 4 (7.84) | 8 (10.96) | 2 (10) | 10 (9.62) | ||
| Refractory/relapse multiple myeloma | 9 (7.26) | 6 (11.76) | 3 (4.11) | 3 (15) | 6 (5.77) | ||
| Non-Hodgkin lymphoma | 5 (4) | 0 | 5 (6.85) | 0 | 5 (4.81) | ||
| Another lymphoma | 13 (10.48) | 5 (9.8) | 8 (10.96) | 1 (5) | 12 (11.54) | ||
| Another leukemia | 6 (4.83) | 2 (3.92) | 4 (5.1) | 1 (5) | 5 (4.81) | ||
| Previous admission history – N (%) | |||||||
| History of ICU admission within 3 months | 19 (15.32) | 11 (21.57) | 8 (10.96) | 0.131 | 5 (25) | 14 (13.46) | 0.190 |
| History of positive hemoculture | 30 (24.2) | 16 (31.37) | 14 (19.18) | 0.139 | 7 (35) | 23 (22.12) | 0.256 |
| History of febrile neutropenia | 62 (50) | 24 (47.06) | 38 (52.05) | 0.715 | 9 (45) | 53 (50.96) | 0.823 |
| Vital signs | |||||||
| Temp (C0) | 38.5 ± 1 | 38.6 ± 1.26 | 38.4 ± 0.95 | 0.456 | 38.42 ± 1.06 | 38.47 ± 1.1 | 0.873 |
| Heart rate beats/min | 110 ± 24 | 109 ± 27 | 111 ± 22 | 0.585 | 118 ± 27 | 109 ± 23 | 0.122 |
| RR breaths/min | 23 ± 5 | 25 ± 6 | 21 ± 4 | 0.001 | 28 ± 7 | 22 ± 4 | <0.001 |
| mABP mmHg | 83 ± 17 | 79 ± 19 | 86 ± 15 | 0.010 | 81 ± 19 | 84 ± 17 | 0.553 |
| SBP mmHg | 118 ± 25 | 110 ± 26 | 122 ± 24 | 0.010 | 113 ± 23 | 118 ± 26 | 0.454 |
| DBP mmHg | 66 ± 15 | 62 ± 17 | 68 ± 13 | 0.043 | 65 ± 18 | 66 ± 14 | 0.745 |
| Mental status – N (%) | |||||||
| A | 112 (90) | 44 (86.27) | 68 (93.15) | 0.404 | 18 (90) | 94 (90) | 0.417 |
| V | 5 (4) | 3 (5.8) | 2 (2.7) | 2 (10) | 3 (2.8) | ||
| P | 7 (6) | 4 (7.8) | 3 (4) | 0 | 7 (6.7) | ||
| WBC ×103 | 10.61±28.9 | 13.98 ± 37.9 | 8.26 ± 20.31 | 0.285 | 26.52 ± 58.66 | 7.55 ± 17.37 | 0.006 |
| Absolute neutrophil /mm3 × 103 | 3.35±5.07 | 3.14±4.23 | 3.50±5.60 | 0.767 | 2.52±3.00 | 3.51± 2.46 | 0.433 |
| Febrile neutropenia | 65 (52.4) | 26 (51) | 39 (53.4) | 0.855 | 10 (50) | 55 (52.8) | 1.00 |
| Hct % | 27% ± 6% | 26.3 ± 6.3% | 27.32± 5.7% | 0.354 | 24.8 ± 6.2% | 27.3 ± 5.9% | 0.083 |
| PLT × 103 | 83.2 ± 96.8 | 80.2 ± 101.7 | 85.3 ± 93.9 | 0.775 | 76.9 ± 117.1 | 84.41 ± 93.0 | 0.753 |
| Cr mg/dl | 1.12± 0.78 | 1.29 ± 0.78 | 1.06 ± 0.82 | 0.070 | 1.52 ± 10 | 1.05 ± 0.75 | 0.023 |
| Total bilirubin (mg/dl) | 1.5 ± 2.16 | 1.4 ± 1.4 | 1.6 ± 2.6 | 0.756 | 2.01 ± 1.9 | 1.4 ± 2.20 | 0.254 |
| Direct bilirubin (mg/dl) | 0.82± 1.53 | 0.82 ± 1.06 | 0.82 ± 1.8 | 0.994 | 1.26 ± 1.5 | 0.73 ± 1.53 | 0.155 |
| INR | 1.21± 0.45 | 1.33 ± 0.5 | 1.14 ± 0.37 | 0.016 | 1.56 ± 0.6 | 1.15 ± 0.37 | 0.001 |
| Alb (mg/dl) | 28.2 ± 6.1 | 25 ± 5.6 | 30 ± 5.6 | <0.001 | 22.5 ± 4.1 | 29.3 ± 5.8 | <0.001 |
| Glucose (mg/dl) | 157 ± 100 | 183 ± 142 | 138 ± 49 | 0.013 | 178 ± 87 | 153 ± 103 | 0.334 |
| Lactate | 2.4 ± 2.2 | 3.1 ± 3.1 | 1.8 ± 0.9 | 0.001 | 3.8 ± 4 | 2.0 ± 1.50 | 0.001 |
| Chest X-ray New infiltration | 39 (31.45) | 29 (56.8) | 10 (13.7%) | <0.001 | 15 (75%) | 24 (23%) | <0.001 |
| Pulmonary | 41 (33.06) | 25 (49.02) | 16 (21.92) | 0.005 | 12 (60) | 29 (27.90) | 0.145 |
| Skin | 13 (10.48) | 4 (7.84) | 9 (12.33) | 3 (15) | 10 (9.62) | ||
| qSOFA ≥ 2 | 20 (16.1) | 16 (31.4) | 4 (5.5) | <0.001 | 7 (35) | 13 (12.5) | 0.023 |
| SOFA ≥ 4 | 84 (67.7) | 44 (86.3) | 40 (54.8) | <0.001 | 17 (85) | 67 (64.4) | 0.115 |
| REWS ≥ 4 | 51 (41.1) | 26 (51) | 25 (34.2) | 0.067 | 11 (55) | 40 (38.5) | 0.216 |
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphoid leukemia; DLBCL, diffused large B-cell lymphoma; A, Alert; V, response by Verbal; P, response by Pain; Hct, hematocrit; PLT, platelet; INR, International Normalized Ratio; Alb, albumin.
Figure 2ROC curves and AUROC of qSOFA, SOFA and REWS score for predicting serious complications at ER (P-value of difference between three AUCs: qSOFA vs SOFA vs REWS 0.004).
Figure 3ROC curves and AUROC of qSOFA, SOFA and REWS score for predicting 28-day mortality (P-value of difference between three AUCs: qSOFA vs SOFA vs REWS 0.253).
Sensitivities and Specificities for qSOFA, SOFA and REWS
| Score | Serious Complication | 28-Days Mortality | ||
|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | Sensitivity (%) | Specificity (%) | |
| ≥1 | 86.3 | 46.6 | 90 | 37.5 |
| ≥2† | 31.4 | 94.5 | 35 | 87.5 |
| ≥3 | 5.9 | 100 | 5 | 98.1 |
| ≥1 | 96.1 | 12.3 | 100 | 3.8 |
| ≥2 | 88.2 | 76.1 | 100 | 10.6 |
| ≥3 | 86.3 | 45.2 | 90 | 23.1 |
| ≥4† | 80.4 | 72.6 | 85 | 35.6 |
| ≥5 | 66.7 | 87.7 | 80 | 56.7 |
| ≥6 | 51.0 | 91.8 | 65 | 71.2 |
| ≥7 | 41.2 | 95.9 | 55 | 79.8 |
| ≥8 | 27.5 | 98.6 | 45 | 85.6 |
| ≥9 | 15.7 | 100 | 30 | 91.3 |
| ≥1 | 88.2 | 15.1 | 85 | 13.5 |
| ≥2 | 82.4 | 20.5 | 75 | 18.3 |
| ≥3 | 68.6 | 45.2 | 70 | 41.3 |
| ≥4† | 51.0 | 65.8 | 55 | 61.5 |
| ≥5 | 41.2 | 80.8 | 45 | 75 |
| ≥6 | 23.5 | 91.8 | 30 | 88.5 |
| ≥7 | 11.8 | 95.9 | 20 | 95.2 |
| ≥8 | 7.8 | 98.6 | 10 | 97.1 |
| ≥9 | 5.9 | 100 | 5 | 98.1 |
Note: †The standard threshold cut-off points were cited from previous research.